[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2383114A1 - Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions - Google Patents

Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions Download PDF

Info

Publication number
CA2383114A1
CA2383114A1 CA002383114A CA2383114A CA2383114A1 CA 2383114 A1 CA2383114 A1 CA 2383114A1 CA 002383114 A CA002383114 A CA 002383114A CA 2383114 A CA2383114 A CA 2383114A CA 2383114 A1 CA2383114 A1 CA 2383114A1
Authority
CA
Canada
Prior art keywords
benzazocines
methano
hexahydro
substituted
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002383114A
Other languages
French (fr)
Other versions
CA2383114C (en
Inventor
Matthias Grauert
Adrian Carter
Thomas Weiser
Helmut Ensinger
Wolfram Gaida
Joachim Mierau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383114A1 publication Critical patent/CA2383114A1/en
Application granted granted Critical
Publication of CA2383114C publication Critical patent/CA2383114C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to substituted 1,2,3,4,5,6-hexahydro-2,6-methano-benzazocines of general formula 1:

(see formula I) wherein the groups R1, R2, R3, R3', R4, R5, R6, X and A may have the meanings given in the specification and claims, processes for preparing them and their use as pharmaceutical compositions.
CA002383114A 1999-11-27 2000-11-21 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions Expired - Fee Related CA2383114C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19957156.2 1999-11-27
DE19957156A DE19957156A1 (en) 1999-11-27 1999-11-27 New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders
PCT/EP2000/011585 WO2001051471A1 (en) 1999-11-27 2000-11-21 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments

Publications (2)

Publication Number Publication Date
CA2383114A1 true CA2383114A1 (en) 2001-07-19
CA2383114C CA2383114C (en) 2008-06-17

Family

ID=7930562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383114A Expired - Fee Related CA2383114C (en) 1999-11-27 2000-11-21 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions

Country Status (33)

Country Link
EP (1) EP1235809B1 (en)
JP (1) JP2003519687A (en)
KR (1) KR20020058042A (en)
CN (1) CN1177825C (en)
AR (1) AR026586A1 (en)
AT (1) ATE254108T1 (en)
AU (1) AU5789701A (en)
BG (1) BG106682A (en)
BR (1) BR0015786A (en)
CA (1) CA2383114C (en)
CO (1) CO5251469A1 (en)
CZ (1) CZ20022120A3 (en)
DE (2) DE19957156A1 (en)
DK (1) DK1235809T3 (en)
EA (1) EA005681B1 (en)
EE (1) EE200200267A (en)
ES (1) ES2210036T3 (en)
HK (1) HK1052176A1 (en)
HR (1) HRP20020460A2 (en)
HU (1) HUP0204169A3 (en)
IL (1) IL149607A0 (en)
MX (1) MXPA02003822A (en)
NO (1) NO20022457D0 (en)
NZ (1) NZ519758A (en)
PL (1) PL355493A1 (en)
PT (1) PT1235809E (en)
SK (1) SK9302002A3 (en)
TR (1) TR200302031T4 (en)
UA (1) UA72566C2 (en)
UY (1) UY26448A1 (en)
WO (1) WO2001051471A1 (en)
YU (1) YU37902A (en)
ZA (1) ZA200204056B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE10204276A1 (en) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceuticals
CA2890655A1 (en) * 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121821A1 (en) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg NEW BENZOMORPHANE AND ITS USE AS A MEDICAMENT
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
DE19740110A1 (en) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma New hydroxy substituted benzomorphan derivatives
DE19907874A1 (en) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma New N-substituted hexahydro-2,6-methano-3-benzazocin-10-ol derivatives, as tension-dependent sodium channel blockers useful for treating e.g. arrhythmia, spasms, pain or neurodegenerative diseases

Also Published As

Publication number Publication date
EA200200491A1 (en) 2002-12-26
NZ519758A (en) 2004-05-28
PL355493A1 (en) 2004-05-04
CO5251469A1 (en) 2003-02-28
MXPA02003822A (en) 2002-12-13
DE19957156A1 (en) 2001-05-31
HUP0204169A2 (en) 2003-03-28
AR026586A1 (en) 2003-02-19
UY26448A1 (en) 2001-06-29
HRP20020460A2 (en) 2003-10-31
JP2003519687A (en) 2003-06-24
HUP0204169A3 (en) 2005-03-29
YU37902A (en) 2005-07-19
ES2210036T3 (en) 2004-07-01
CN1399630A (en) 2003-02-26
EA005681B1 (en) 2005-04-28
TR200302031T4 (en) 2004-01-21
CZ20022120A3 (en) 2002-09-11
SK9302002A3 (en) 2002-11-06
EE200200267A (en) 2003-06-16
EP1235809B1 (en) 2003-11-12
PT1235809E (en) 2004-04-30
NO20022457L (en) 2002-05-24
WO2001051471A1 (en) 2001-07-19
DE50004455D1 (en) 2003-12-18
AU5789701A (en) 2001-07-24
ZA200204056B (en) 2003-07-30
EP1235809A1 (en) 2002-09-04
CN1177825C (en) 2004-12-01
CA2383114C (en) 2008-06-17
KR20020058042A (en) 2002-07-12
NO20022457D0 (en) 2002-05-24
BG106682A (en) 2003-01-31
DK1235809T3 (en) 2004-03-15
IL149607A0 (en) 2002-11-10
UA72566C2 (en) 2005-03-15
HK1052176A1 (en) 2003-09-05
BR0015786A (en) 2002-08-13
ATE254108T1 (en) 2003-11-15

Similar Documents

Publication Publication Date Title
CA2425560A1 (en) Anticholinergics, processes for preparing them and their use as pharmaceutical compositions
CA2414095A1 (en) Novel compounds
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
CA2243504A1 (en) New 19-nor-pregnene derivatives
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
CA2278201A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene, and processes for their preparation
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
CA2334773A1 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
BG103485A (en) Ketobanzamides as calpain inhibitors
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
CA2475113A1 (en) Isothiazole derivatives useful as anticancer agents
CA2223094A1 (en) Phenylpyridazinones
CA2402431A1 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
WO2001017973A3 (en) Novel herbicides
IL112622A0 (en) Camptothecin derivatives, their preparation and pharmaceutical compositions containing them
CA2373117A1 (en) 13-methyl-erythromycin derivatives
WO2003018553A8 (en) Oral antidiabetic agents
CA2286511A1 (en) Novel macrolide derivatives
CA2322195A1 (en) Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
CA2382322A1 (en) Aminocarbonyl-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
CA2356985A1 (en) 5ht1 antagonists for antidepressant therapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed